Large-volume parenteral films for 0.9% sodium chloride, 5% dextrose, and Ringer’s lactate require a product-contact layer that does not contribute trace organic extractables during terminal steam sterilization at 121°C for 15 min with F₀ ≥ 15. A five-layer blown-film configuration is specified with metallocene-catalyzed linear low-density polyethylene at 70–80% of total thickness, homopolymer polypropylene exterior at 15–22%, and maleic anhydride grafted polyolefin tie resin at 5–8%. Total film thickness is 190–220 µm, and layer-thickness uniformity is held within ±5% across the web because excursions above 8% in the tie layer generate seal variability on bag-forming lines. The compliance set includes USP <661.1>, USP <661.2>, Ph. Eur. 3.1.6, Ph. Eur. 3.1.4/3.1.5, 21 CFR 177.1520, USP <88> Class VI, and ISO 10993-5. Processing begins on a five-layer coextrusion blown-film line with die gap 1.8–2.4 mm, feed-block temperature profile 180–240°C, die temperature held at 220–230°C, melt filtration through 100–200 µm screens, blow-up ratio 1.8–2.2, and frost line height 600–900 mm; bubble cooling uses chilled air at 12–18°C, and collapse is performed through a low-tension nip to prevent blocking of the polyethylene contact surface. Downstream bag conversion uses heated-tool welding at 160–180°C and 0.3–0.5 MPa for 2–5 s to seal polypropylene-to-polypropylene port flanges, while peripheral seals are formed polyethylene-to-polyethylene at 130–150°C. Converter seal strength is validated per ASTM F88/F88M-21, with a minimum peripheral seal strength of 3 N/15 mm. The terminal product range includes 100 mL, 250 mL, 500 mL, and 1000 mL bags for sterile water for injection, 0.9% sodium chloride, 5% dextrose, and Ringer’s lactate. A process conflict arises at sterilization because polypropylene retains dimensional stability at 121°C while linear low-density polyethylene softens; without the tie layer, autoclave pressure pulses of 0.2–0.25 MPa delaminate the film at the polypropylene/polyethylene interface, and port-seal rupture occurs when the polyethylene contact layer exceeds 220 µm.

Why Do Terminal Sterilization Cycle Demands Drive Layer-Ratio Design in Small-Volume Oncology Diluent Bags?

For small-volume parenteral containers of 50 mL and 100 mL used as diluents for cytotoxic drug admixture, the controlling failure mode is chemical transfer rather than mechanical burst. The specified film has total thickness 150–180 µm, with product-contact metallocene-catalyzed linear low-density polyethylene at 75–85%, outer polypropylene homopolymer at 10–18%, and tie resin at 5–8%. Antistatic or slip additives are excluded from the product-contact layer; if static control is required, the additive masterbatch is confined to the outer polypropylene layer at 0.05–0.12 wt%. Compliance includes USP <1663> extractables study design, USP <1664> leachables acceptance, Ph. Eur. 3.1.6, ISO 10993-18 chemical characterization, USP <87> biological reactivity in vitro, USP <88> Class VI, ISO 10993-4 hemocompatibility, and ISO 15378 primary packaging quality management. Film production is conducted in an ISO 7 cleanroom using a low-gel cast or blown coextrusion line, and slitting is performed with tungsten carbide blades without silicone lubricants. Bag conversion on automated equipment inserts polypropylene ports with heated dies at 165–185°C, seal width 4–6 mm, and clamp force 0.3–0.5 MPa; filling is conducted under Grade A laminar flow. Terminal products include 50 mL and 100 mL bags of 0.9% sodium chloride and 5% glucose for injection used as diluents for methotrexate, fluorouracil, cyclophosphamide, and related antineoplastic admixtures. The film is not supplied as a certified cytotoxic containment system; drug-specific sorption, pH-shift, and leachable validation under ICH Q1A/R2 remains mandatory because methotrexate and fluorouracil sorption varies with concentration, temperature, and dwell time. Port-seal leakage observed in end-user hand manipulation has been traced to outer polypropylene layer thickness below 12% or to seal temperatures below 160°C; published data for this specific configuration is limited, so converter installation qualification must establish the lower seal-temperature limit on the target line.

At high-speed form-fill-seal lines for moisture-tolerant tablet and capsule strips, a 60–100 µm polypropylene/polyethylene multilayer film is used only when the drug product is not classified as highly moisture-sensitive or when a desiccant is included in secondary packaging. The layer split is outer polypropylene at 20–30%, tie resin at 5–10%, and polyethylene contact layer at 60–75%; an antistatic masterbatch is confined to the outer polypropylene at 0.05–0.10 wt%. Compliance anchors are USP <661.1>, USP <661.2>, USP <671> container performance for solid oral dosage forms, Ph. Eur. 3.1.4/3.1.5/3.1.6, and 21 CFR 177.1520. On vertical or horizontal FFS machines, the film is folded so that polyethylene seals to polyethylene at 120–150°C, dwell 0.3–0.8 s, and sealing pressure 0.4–0.6 MPa; sealing jaws are PTFE-coated because the polypropylene outer layer has a seal-initiation temperature above 145°C. Outputs of 25–45 cycles/min are typical for strip packaging of 10-tablet and 10-capsule strips and 1–5 g granule sachets. The principal process conflict is web inversion at the unwind or forming shoulder: if the polypropylene side contacts the sealing jaw, heat transfer to the polyethylene seal layer is delayed and seal strength falls below 3 N/15 mm when tested per ASTM F88/F88M-21. A water vapor transmission rate below 0.5 g/m²/day at 38°C and 90% RH is not achievable with this olefin-only structure; aluminum foil or PVdC-coated film is required for highly moisture-sensitive formulations, and ASTM F1249-20 is used to establish the moisture budget for each formulation.

When Bulk API Liners Replace Aluminum-Foil Interleaving in Drum and FIBC Packaging

For bulk tablet, capsule, and granule active pharmaceutical ingredient powders packed in high-density polyethylene drums or flexible intermediate bulk containers, a 150–250 µm polypropylene/polyethylene multilayer liner functions as a moderate-barrier contact layer, not as an oxygen or moisture barrier equivalent to aluminum foil. The layer distribution is outer polypropylene at 25–35%, maleic anhydride grafted polyolefin tie at 5–10%, and polyethylene contact layer at 60–70%; anti-static concentrate may be incorporated in the outer layer at 0.05–0.20 wt%. Compliance includes ICH Q7 packaging material control, USP <661.1>/661.2>, Ph. Eur. 3.1.6, 21 CFR 177.1520, and ISO 15378. The film is converted on a blown-film line into lay-flat tubing, gusseted to the required drum diameter, and cut into 25–200 L liners; bottom seals are produced by thermal impulse welding at 170–200°C, and the inner surface is left without corona treatment to reduce surface oxidation and particle adhesion. Filling occurs at 20–25°C and ≤ 40% RH in API packaging suites, with nitrogen purge used when the API has headspace oxygen sensitivity. Terminal products include 25 kg and 50 kg drum liners and 500 kg FIBC liners for tablet, capsule, and granule APIs and intermediates. Oxygen transmission rate testing per ASTM D3985-17 should be performed on the finished liner rather than on flat film because gusset creases can create localized thinning; published data for this specific configuration is limited, and substitution for aluminum-foil interleaving is valid only after the drug product’s oxidative degradation thresholds have been quantified.

Single-Dose Oral Granule and Powder Sachets: Seal Integrity Under Filling Dust

Vertical form-fill-seal conversion of oral reconstitutable powders, coated granules, and taste-masked pellets requires a 70–100 µm multilayer polypropylene/polyethylene film whose seal layer tolerates dust contamination at the seal area without producing channel leakers. The outer polypropylene layer is 15–25%, tie resin 5–8%, and polyethylene contact layer 70–80%; anti-block is confined to the outer polypropylene layer at 0.05–0.10 wt%. Compliance includes USP <661.1>/661.2>, USP <671>, Ph. Eur. 3.1.4/3.1.5/3.1.6, and 21 CFR 177.1520. The FFS sequence forms the sachet with polyethylene-to-polyethylene seals at 120–155°C, dwell 0.4–1.0 s, and pressure 0.4–0.6 MPa; textured sealing jaws and local dust extraction are required because powder fines at the seal area reduce seal strength below 3 N/15 mm per ASTM F88/F88M-21. Terminal products include 1–5 g single-dose sachets for oral suspension, solution, or direct administration of granules and coated pellets. Seal-channel leaks are detected in routine in-process checks by dye penetration per ASTM F1929-15, and the operational boundary is that ambient relative humidity above 60% RH during conversion increases film blocking and requires pre-drying of the anti-block masterbatch before extrusion and reduction of unwind tension during slitting.

Sterile irrigation and wash solutions represent a less extractables-critical but still pharma-grade segment where the same polypropylene/polyethylene multilayer film is qualified under USP <661.1>/661.2>, USP <88> Class VI, ISO 10993-4, ISO 10993-5, ISO 10993-10, and ISO 10993-11. The film construction is 180–200 µm total thickness, with outer polypropylene at 20–25%, tie resin at 5–8%, and polyethylene contact layer at 70–75%. Blown-film production is followed by bag welding and port insertion at 160–180°C, and terminal steam sterilization is performed at 121°C for 15 min. Terminal products include 500 mL and 1000 mL irrigation bags for sterile water, 0.9% sodium chloride, and urological wash solutions. Particulate burden is controlled by USP <788> light obscuration on the filled container, and the film is not specified for lipid-containing irrigation fluids because lipid penetration into the polyethylene contact layer alters heat-seal strength after extended storage.